Therapeutic effects were observed with both CAR-T cells and trastuzumab in the MDA-MB-231HER2+ breast tumor xenograft model, with anti-HER2-13 CAR-T cells demonstrating slightly enhanced efficacy and no evident off-target toxicity. The gene discussed is ERBB2; the disease is breast neoplasm.